Literature DB >> 20977291

Oligonucleotide delivery in cancer therapy.

Giuseppe De Rosa1, Daniela De Stefano, Aldo Galeone.   

Abstract

IMPORTANCE OF THE FIELD: Cancer is frequently caused by altered protein expression. Oligonucleotides (ONs) are short synthetic nucleic acid fragments, able to selectively correct protein expression into cells by different mechanisms. However, biological barriers hamper the therapeutic use of ONs without suitable delivery strategies. AREAS COVERED IN THIS REVIEW: This review summarizes the most meaningful non-viral strategies for ON delivery, including the chemical modifications of the ON backbone and non-viral delivery systems. WHAT THE READER WILL GAIN: The reader will gain an update of the main strategies for ON delivery in cancer. Advantages and limits of each approach are underlined. Emphasis is given to the delivery strategies that contributed to bringing ONs into clinical trials. TAKE HOME MESSAGE: In the long story of ONs for cancer therapy, the development of delivery strategies has led, in the last few years, to different opportunities to use the high therapeutic potential of these molecules in humans.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20977291     DOI： 10.1517/17425247.2010.527942

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN： 1742-5247            Impact factor:   6.648


  7 in total

Review 1.  Promises and challenges of MicroRNA-based treatment of multiple myeloma.

Authors:  P Tagliaferri; M Rossi; M T Di Martino; N Amodio; E Leone; A Gulla; A Neri; P Tassone
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

Review 2.  Gene interference strategies as a new tool for the treatment of prostate cancer.

Authors:  Mariarosaria Boccellino; Concetta Alaia; Gabriella Misso; Alessia Maria Cossu; Gaetano Facchini; Raffaele Piscitelli; Lucio Quagliuolo; Michele Caraglia
Journal:  Endocrine       Date:  2015-06-07       Impact factor: 3.925

3.  Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.

Authors:  Immacolata Scognamiglio; Maria Teresa Di Martino; Virginia Campani; Antonella Virgilio; Aldo Galeone; Annamaria Gullà; Maria Eugenia Gallo Cantafio; Gabriella Misso; Pierosandro Tagliaferri; Pierfrancesco Tassone; Michele Caraglia; Giuseppe De Rosa
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

Review 4.  Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer.

Authors:  Virginia Campani; Giuseppina Salzano; Sara Lusa; Giuseppe De Rosa
Journal:  Nanomaterials (Basel)       Date:  2016-07-09       Impact factor: 5.076

5.  In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.

Authors:  Maria Teresa Di Martino; Virginia Campani; Gabriella Misso; Maria Eugenia Gallo Cantafio; Annamaria Gullà; Umberto Foresta; Pietro Hiram Guzzi; Maria Castellano; Anna Grimaldi; Vincenzo Gigantino; Renato Franco; Sara Lusa; Mario Cannataro; Pierosandro Tagliaferri; Giuseppe De Rosa; Pierfrancesco Tassone; Michele Caraglia
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

Review 6.  Mir-34: a new weapon against cancer?

Authors:  Gabriella Misso; Maria Teresa Di Martino; Giuseppe De Rosa; Ammad Ahmad Farooqi; Angela Lombardi; Virginia Campani; Mayra Rachele Zarone; Annamaria Gullà; Pierosandro Tagliaferri; Pierfrancesco Tassone; Michele Caraglia
Journal:  Mol Ther Nucleic Acids       Date:  2014-09-23       Impact factor: 10.183

7.  Vector-independent transmembrane transport of oligodeoxyribonucleotides involves p38 mitogen activated protein kinase phosphorylation.

Authors:  Minyuan Peng; Yanming Li; Jian Zhang; Yong Wu; Xiaoyang Yang; Ye Lei; Mao Ye; Jing Liu; Xu Han; Yijin Kuang; Xielan Zhao; Fangping Chen
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.